A recent study has revealed that a vaccine administered during pregnancy has successfully reduced hospital admissions for infants suffering from respiratory syncytial virus (RSV) by over 80%. This development represents a significant stride in public health, particularly for the approximately 20,000 infants who face severe illness due to RSV in the UK each year. The vaccine, which has been available to pregnant women since 2024, offers vital protection during a critical period when newborns are especially vulnerable to respiratory infections.
Significant Impact of the RSV Vaccine
The introduction of the RSV vaccine in the UK came after extensive clinical trials demonstrated its effectiveness in enhancing maternal immunity. By immunising expectant mothers from 28 weeks of gestation, the vaccine facilitates the transfer of protective antibodies to the unborn child through the placenta, ensuring that newborns receive essential immunity from birth.
Research conducted by the UK Health Security Agency (UKHSA) indicates that this vaccine provides nearly 85% protection against RSV when administered at least four weeks prior to delivery. Moreover, even vaccinations given closer to the birth date can still confer some level of protection, highlighting the vaccine’s flexibility in safeguarding infants.
Dr Conall Watson, who leads the national RSV programme at UKHSA, emphasises the importance of timely vaccination. “If you’ve got a longer interval between when the vaccine is given and when the baby is born, you get even better protection,” he notes. “Get it on time. But if you can’t, do get vaccinated throughout the third trimester.”
The Burden of RSV on Infants
RSV is a primary cause of hospitalisation among infants under one year of age. The virus can manifest as anything from mild respiratory symptoms to severe infections that result in hospital stays and, in rare cases, fatalities. According to Dr Watson, witnessing an infant struggling for breath due to an RSV infection is a distressing experience for parents, one that can lead to significant anxiety and fears about their child’s health.
Statistics from the recent study, which tracked nearly 300,000 births in England between September 2024 and March 2025, reveal that a substantial number of hospital admissions for RSV primarily involved infants whose mothers were not vaccinated. This data underscores the critical role that maternal vaccination plays in protecting newborns.
Personal Stories Highlight the Vaccine’s Importance
The case of young Malachi, now 12, illustrates the potential consequences of RSV infections in unvaccinated infants. After developing a cold as a baby, Malachi’s condition rapidly worsened, resulting in hospitalisation for oxygen support and subsequent brain damage. His mother, Laine Lewis, shares her experience to encourage vaccination among other expectant mothers. “I’d encourage people to take the vaccine for RSV because it will help their child,” she states, noting that while the severity of her son’s case is rare, the risks associated with RSV are real.
As the vaccine programme progresses, Dr Watson continues to advocate for its uptake, particularly as the winter months pose increased risks for respiratory illnesses. Currently, approximately 64% of pregnant women in England are receiving the RSV vaccine, although this figure drops to 53% in London, indicating a need for heightened awareness and education regarding the importance of vaccination.
Broader Vaccination Initiatives
In addition to the RSV vaccine, pregnant women are advised to receive vaccinations for flu and whooping cough, both of which pose additional risks during pregnancy. Furthermore, adults over the age of 75, as well as those residing in care homes, are also eligible for the RSV vaccine, extending its protective benefits beyond just newborns.
Why it Matters
The introduction of the RSV vaccine for pregnant women marks a pivotal moment in public health strategy, as it not only significantly reduces the risk of severe respiratory illness in newborns but also underscores the importance of maternal vaccination. With the potential to prevent thousands of hospital admissions each year, this initiative serves as a critical tool in safeguarding the health of infants and alleviating parental concerns during a vulnerable time. As awareness and vaccination rates improve, we may witness a substantial decline in RSV-related hospitalisations, ultimately leading to healthier beginnings for countless children.
